Antiviral natural products against chronic hepatitis B: Recent developments

Current Pharmaceutical Design

Volumn 22, Issue 3, 2016, Pages 286-293

  Parvez, Mohammad K ^a   Arbab, Ahmed H ^a   Al Dosari, Mohammed S ^a   Al Rehaily, Adnan J ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antivirals; HBV; Hepatitis B; Natural products; Nucleos(t)ide analogs; Phytochemicals

Indexed keywords

ADEFOVIR; ALKALOID DERIVATIVE; ALPHA INTERFERON; ANTIVIRUS AGENT; ARTEMISININ; ASTRAGALOSIDE IV; ENTECAVIR; FLAVONOID; GERANIIN; HELIOXANTHIN; LAMIVUDINE; LIGNAN DERIVATIVE; NATURAL PRODUCT; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; OXYMATRINE; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; SAPONIN DERIVATIVE; TENOFOVIR; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VOGONIN;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS B; DNA REPLICATION; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; FULMINANT HEPATIC FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; MEDICINAL PLANT; MICROBIAL SENSITIVITY TEST; PROCEDURES; VIROLOGY;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PLANT PREPARATIONS; PLANTS, MEDICINAL;

EID: 84962621471     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151112152733     Document Type: Article

References (60)

1. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2: 50-7.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-25.
3. El-Hazmi MA. Hepatitis B virus in Saudi Arabia. J Trop Med Hyg 1989; 92: 56-61.
4. André F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18: S20-2.
5. Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res 2015; 121: 82-93.
6. Poordad F, Chee GM. Viral resistance in hepatitis B: prevalence and management. Curr Gastroenterol Rep 2010; 12: 62-9.
7. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-13.
8. Adoga MP, Gyar SD, Pechulano S, et al. Hepatitis B virus infections in apparently healthy urban Nigerians: data from prevaccination tests. J Infect Dev Ctries 2010; 4: 397-400.
9. Rumi MA, Begum K, Hassan MS, et al. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery: implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998; 59: 318-22.
10. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13: 48-64.
11. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39.
12. Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma World J Gastroenterol 2011; 17: 4853-7.
13. Eisenstein M. Vaccines: Know your enemy. Nature 2011; 471: S8-9.
14. Banker DD. Viral hepatitis (Part-II). Indian J Med Sci 2003; 57: 415-24.
15. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
16. WHO. The world health report 2002: reducing risks, promoting healthy life 2002. http://www.who.int/whr/2002/en/
17. Elgouhari HM, Abu-Rajab Tamimi TI, Carey W. Hepatitis B: a strategy for evaluation and management. Cleve Clin J Med 2009; 76: 19-35.
18. WHO. Weekly Epidemiol Rec 2004; 79: 253-64. http://www.who.int/wer/2004/wer7928/en/.
19. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
20. Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001; 12: 1-35.
21. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999; 12: 81-95.
22. Gupta V, Ul-Hussain J, Vijay S. Hepatitis-B: Recent Treatment. JK Sci 2006; 1: 9-13.
23. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66: 2715-25.
24. Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules 2010; 15: 5878-908.
25. Scott JD, McMahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009; 11: 28-36.
26. Verpoorte R. Pharmacognosy in the new millennium: leadfinding and biotechnology. J Pharm Pharmacol 2000; 52: 253-62.
27. Chattopadhyay D, Sarkar MC, Chatterjee T, et al. Recent advancements for the evaluation of anti-viral activities of natural products. N Biotechnol 2009; 25: 347-68.
28. Naithani R, Mehta RG, Shukla D et al. Dietry Components and Immune Function. In: Health and Nutrition. Ed. Adriana Bendich 2010; 421-67.
29. Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 2010; 4: 39-47.
30. Guo Q, Zhao L, You Q, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res 2007; 74: 16-24.
31. Wohlfarth C, Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin 2009; 30: 25-30.
32. Wu LL, Yang XB, Huang ZM, Liu HZ, Wu GX. In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik. Acta Pharmacol Sin 2007; 28: 404-9.
33. He W, Li LX, Liao QJ, Liu CL, Chen XL. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication-inducible cell line. World J Gastroenterol 2011; 17: 1507-14.
34. Wang GF, Shi LP, Ren YD, et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res 2009; 83: 186-90.
35. Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology 2010; 51: 690-8.
36. Kang EH, Kown TY, Oh GT, et al. The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res 2006; 72: 100-6.
37. Li J, Huang H, Zhou W, Feng M, Zhou P. Anti-hepatitis B virus activities of Geranium carolinianum L. extracts and identification of the active components. Biol Pharm Bull 2008; 31: 743-7.
38. Zhou Z, Zhang Y, Ding XR, et al. Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo. Antiviral Res 2007; 74: 59-64.
39. Wu XN, Wang GJ. Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections. Chin J Dig Dis 2004; 5: 12-6.
40. Xu WS, Zhao KK, Miao XH, et al. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol 2010; 16: 2028-37.
41. Mao YM, Zeng MD, Lu LG, et al. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 2004; 10: 3269-73
42. Li HL, Han T, Liu RH, Zhang C, Chen HS, Zhang WD. Alkaloids from Corydalis saxicola and their anti-hepatitis B virus activity. Chem Biodivers 2008; 5: 777-83.
43. Cheng P, Ma YB, Yao SY, et al. Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. Bioorg Med Chem Lett 2007; 17: 5316-20.
44. Zhao YL, Cai GM, Hong X, Shan LM, Xiao XH. Anti-hepatitis B virus activities of triterpenoid saponin compound from Potentilla anserine L. Phytomedicine 2008; 15: 253-8.
45. Wang S, Li J, Huang H, et al. Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull 2009; 32: 132-5.
46. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008; 47: 804-11.
47. Chaturvedi D. In: Oppor Chall Scope Natl Prod Med Chem 2011; 313-34.
48. Tian Y, Sun LM, Li B, Liu XQ, Dong JX. New anti-HBV caryophyllane-type sesquiterpenoids from Euphorbia humifU S A Willd. Fitoterapia. 2011; 82: 251-4.
49. Zhao G, Yin Z, Dong J. Antiviral efficacy against hepatitis B virus replication of oleuropein isolated from Jasminum officinale L. var. grandiflorum. J Ethnopharmacol 2009; 125: 265-8.
50. Geng CA, Wang LJ, Zhang XM, et al. Anti-hepatitis B virus active lactones from the traditional Chinese herb: Swertia mileensis. Chemistry 2011; 17: 3893-903.
51. He K, Ma YB, Geng CA, et al. Anti-hepatitis B virus active secoiridoids from Swertia kouitchensis. Nat Prod Bioprospect 2011; 1: 48-51.
52. Li Y, Fu L, Yeo H, et al. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative. Antivir Chem Chemother 2005; 16: 193-201.
53. Tseng YP, Kuo YH, Hu CP, et al. The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters. Antiviral Res 2008; 77: 206-14.
54. Wei W, Li X, Wang K, Zheng Z, Zhou M. Lignans with antihepatitis B virus activities from Phyllanthus niruri L. Phytother Res. 2012; 26: 964-8.
55. Chen H, Li J, Wu Q, et al. Anti-HBV activities of Streblus asper and constituents of its roots. Fitoterapia 2012; 83: 643-9.
56. Liu JF, Jiang ZY, Geng CA, et al. Two new lignans and anti-HBV constituents from Illicium henryi. Chem Biodivers 2011; 8: 692-8.
57. Li Z, Li LJ, Sun Y, Li J. Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy 2007; 53: 320-6.
58. Sun YW, Liu GM, Huang H, Yu PZ. Chromone derivatives from Halenia elliptica and their anti-HBV activities. Phytochemistry 2012; 75: 169-76.
59. Chou SC, Huang TJ, Lin EH, Huang CH, Chou CH. Antihepatitis B virus constituents of Solanum erianthum. Nat Prod Commun 2012; 7: 153-6.
60. Arbab AH, Parvez MK, Al-Dosari MS, et al. Hepatoprotective and antiviral efficacy of Acacia mellifera leaves fractions against hepatitis B virus. BioMed Res Intl. 2015; 2015: 929131.